Selective mitochondrial superoxide generation in vivo is cardioprotective through hormesis by Antonucci, Salvatore et al.
Contents lists available at ScienceDirect
Free Radical Biology and Medicine
journal homepage: www.elsevier.com/locate/freeradbiomed
Original article
Selective mitochondrial superoxide generation in vivo is cardioprotective
through hormesis
Salvatore Antonuccia,1, John F. Mulveyb,1, Nils Burgerc, Moises Di Santea, Andrew R. Hallc,
Elizabeth C. Hinchyc, Stuart T. Caldwelld, Anja V. Gruszczykc, Soni Deshwala,
Richard C. Hartleyd, Nina Kaludercice, Michael P. Murphyc, Fabio Di Lisaa,e, Thomas Kriegb,∗
a Department of Biomedical Sciences, University of Padova, 35131, Padova, Italy
bDepartment of Medicine, University of Cambridge, Hills Road, Cambridge, CB2 0XY, UK
cMitochondrial Biology Unit, University of Cambridge, Hills Road, Cambridge, CB2 0XY, UK
d School of Chemistry, University of Glasgow, Glasgow, G12 8QQ, UK
eNeuroscience Institute, National Research Council of Italy (CNR), 35131, Padova, Italy
A B S T R A C T
Reactive oxygen species (ROS) have an equivocal role in myocardial ischaemia reperfusion injury. Within the cardiomyocyte, mitochondria are both a major source
and target of ROS. We evaluate the effects of a selective, dose-dependent increase in mitochondrial ROS levels on cardiac physiology using the mitochondria-targeted
redox cycler MitoParaquat (MitoPQ). Low levels of ROS decrease the susceptibility of neonatal rat ventricular myocytes (NRVMs) to anoxia/reoxygenation injury and
also cause profound protection in an in vivo mouse model of ischaemia/reperfusion. However higher doses of MitoPQ resulted in a progressive alteration of
intracellular [Ca2+] homeostasis and mitochondrial function in vitro, leading to dysfunction and death at high doses. Our data show that a primary increase in
mitochondrial ROS can alter cellular function, and support a hormetic model in which low levels of ROS are cardioprotective while higher levels of ROS are
cardiotoxic.
1. Introduction
Ischaemia/reperfusion (I/R) injury occurs when the blood supply to
a region of tissue is disrupted and later restored. Key to the develop-
ment of the pathology is a lack of oxygen for oxidative phosphorylation
within mitochondria. This results in the arrest of forward electron flow
in the respiratory chain [1] due to the lack of oxygen to act as the
terminal electron acceptor. Consequently, succinate is accumulated
during ischaemia by the reduction of fumarate at mitochondrial com-
plex II [2], or from anaplerotic supply of glutamate to the tricarboxylic
acid cycle leading to succinate that cannot be oxidized due to the re-
duced Coenzyme Q pool [3]. At reperfusion, the re-introduction of
oxygen leads to sudden changes in myocardial viability, mediated by a
burst of ROS production within the mitochondria. While a number of
sources of ROS have been proposed to be responsible, recently it has
been shown that the succinate pool accumulated during ischaemia is
rapidly oxidized upon reperfusion, driving ROS production from com-
plex I through reverse electron transport [2]. The sustained opening of
the mitochondrial permeability transition pore (mPTP), a key arbiter of
cell fate, also results in significant ROS production. As ROS are among
the factors contributing to prolonged mPTP opening there is a positive
feedback loop of ROS-induced ROS release [4] through which ROS
generation results in sustained mitochondrial dysfunction and even-
tually cell death [5].
However, aside from their role in driving mPTP-mediated cell da-
mage, mitochondrial ROS production also impacts positively on several
aspects of myocardial I/R injury. Mitochondrial ROS play crucial roles
in signalling processes both within mitochondria and in their interplay
with other cellular sites [6]. Indeed, the protective mechanism under-
lying ischaemic preconditioning (IPC) appears to involve generation of
low levels of ROS [7–9]. This has been demonstrated by showing that
the protective effects of an IPC protocol may be abrogated by anti-
oxidants [10–16], or replicated by the addition of exogenous oxidants
in a pre- or post-conditioning like manner [17–19]. Indeed, it has been
demonstrated that the acute treatment with H2O2 in a model of Lan-
gerdorff perfused hearts elicits cardioprotection in a preconditioning-
like manner depending of its concentration [20,21]. These findings that
ROS can be either cardiotoxic or cardioprotective, depending on the
context, may help explain why the use of general ROS scavengers has
yielded mixed results. For example there are also studies in experi-
mental models that report no effect of antioxidants upon I/R injury
[22–25]. In the clinic, large scale trials with antioxidants have
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produced equivocal effects upon cardiovascular health outcomes
[26,27]. These findings are also consistent with the growing apprecia-
tion for the differential effects of “good” and “bad” ROS [28–30], by
which ROS can either contribute to cell death, or at low levels activate
cardioprotective mechanisms: a concept referred to as ‘hormesis’.
The context in which ROS might lead to these opposing con-
sequences will arise due to differential effects of ROS production in
three primary dimensions: in magnitude, in timing, and in spatial dis-
tribution. A better understanding of, and control of these dimensions
over ROS production may provide mechanistic insights as to how ROS
can have different effects. Here, we address this point by exploring the
role of ROS generated within mitochondria at different concentrations,
and characterize the processes linking changes in mitochondrial ROS
levels to cardiac pathophysiology with focus on cardiac I/R injury. To
investigate the consequences of a primary increase in ROS specifically
within the mitochondrial compartment, we used the mitochondria-
targeted compound MitoParaquat (MitoPQ) [31]. MitoPQ was designed
based upon the conjugation of a paraquat moiety (1,1’-dimethyl-4,4’-
bipyridinium dichloride) [32] with the mitochondria targeting triphe-
nylphosphonium group. At the flavin site of complex I in the electron
transport chain, MitoPQ accepts an electron to generate a radical
monocation that reacts rapidly with oxygen to specifically generate
superoxide, which is the proximal ROS species produced endogenously
[33].
In this work we demonstrate that a selective primary increase in
mitochondrial ROS is a causal factor in changes of mitochondrial and
cell function, and show that low levels of mitochondrial ROS are pro-
tective against ischaemic injury both in vitro and in vivo, while higher
levels are damaging.
2. Results
2.1. MitoPQ induces a primary increase in mitochondrial ROS levels in a
dose-dependent manner
To investigate the effects of mitochondrial ROS production by
MitoPQ in cardiomyocytes, neonatal rat ventricular myocytes (NRVMs)
were treated for 2 h with different doses of MitoPQ. High levels of ROS
were assessed with a reduced form of MitoTracker Red (MTR) that
fluoresces only following oxidation. However, MTR presents some
limitations due to its relative lack of sensitivity and specificity, that its
accumulation depends on cell and mitochondrial membrane potential
(ΔΨm), and these can be affected by different treatments independently
of ROS formation. Therefore, to detect low levels of ROS we used
MitoHyPer, a genetically encoded sensor that is highly specific and
sensitive for sub-micromolar concentrations of mitochondrial H2O2
[34].
MitoPQ caused a significant increase in mitochondrial ROS levels in
a dose-dependent manner that was not observed when cells were pre-
treated with the antioxidant N-(2-Mercaptopropionyl)glycine (MPG)
(Fig. 1A–C). Cells treated with a MitoPQ control compound
(Supplementary Fig. 1) that is structurally similar to MitoPQ but which
does not undergo redox cycling did not show an increase in mi-
tochondrial ROS levels (Fig. 1B–D, Supplementary Fig. 2A and B).
Moreover, cells treated with non-mitochondrial paraquat (PQ) did not
show an increase in mitochondrial ROS levels (Supplementary Fig 2C),
in line with previous reports [31].
Taken together, these data confirm that MitoPQ produces ROS
within mitochondria in a dose-dependent manner.
2.2. A primary increase in mitochondrial ROS levels affects mitochondrial
function in a dose-dependent manner
An increase in mitochondrial ROS production has been reported to
induce a decrease in ΔΨm that is associated with mPTP opening
[35,36]. To investigate whether MitoPQ-induced ROS affect
mitochondrial function, we monitored ΔΨm using tetra-
methylrhodamine fluorescence. NRVMs treated with different doses of
MitoPQ displayed a dose-dependent decrease in ΔΨm (Fig. 2A). No-
tably, although promoting H2O2 formation (Fig. 1C), 0.01 μM MitoPQ
did not affect ΔΨm. However, a defective electron transport chain may
not lead to a detectable decrease in ΔΨm, since in isolated cells the
proton gradient can be maintained by the reverse activity of FOF1 ATP
synthase [37]. This compensatory process was abolished by the pre-
sence of the FOF1 ATPase inhibitor oligomycin in all the experiments.
The lack of ΔΨm variations at low MitoPQ doses suggests that mild ROS
formation is unlikely to alter electron transport chain function. Taken
together, these results show that a primary increase in mitochondrial
ROS formation decreases ΔΨm in a dose-dependent manner, but that
this does not occur at low ROS levels.
Analysing the causal relationship between mPTP, ROS formation
and ΔΨm is complicated by the fact that mPTP opening is both a cause
and a consequence of ΔΨm loss and mitochondrial ROS generation
[38–40]. Hence, we used MitoPQ to investigate the effects of a primary
increase in mitochondrial ROS levels on mPTP induction assessed by
monitoring calcein fluorescence [41,42]. NRVMs were pre-treated with
or without cyclosporine A (CsA), a desensitizer of the mPTP. Since CsA
is also an inhibitor of the multidrug resistance P-glycoproteins (MDR),
which may alter MitoPQ distribution, cells were pre-treated also with
cyclosporine H which inhibits the MDRs but does not affect mPTP
opening [43]. Treatment with 0.5 μM MitoPQ induced a rapid decrease
in calcein fluorescence (∼30%) that was prevented by CsA. MitoPQ-
induced mPTP opening was dependent on ROS formation since it was
abrogated by MPG. Notably, MPG did not display any effect when
mPTP opening was induced by calcimycin (Fig. 2B). Taken together,
these results indicate that ROS induced by 0.5 μM MitoPQ lead to mPTP
opening in NRVMs.
2.3. A primary increase in mitochondrial ROS levels affects cell function
and viability
We hypothesized that mitochondrial ROS would affect cellular sites
and functions outside the mitochondria. In particular, our attention was
focused on [Ca2+]I homeostasis due to its central role in cardiac phy-
siology [44,45]. Treatment with 0.01 μM MitoPQ caused a significant
increase in both amplitude (Fig. 3B) and response of the sarcoplasmic
reticulum to caffeine (Fig. 3E), without affecting the oscillatory pattern
or the frequency of the Ca2+ transients (Fig. 3A–D). In contrast, doses
of MitoPQ>0.01 μM induced dose-dependent alterations in all the
oscillatory parameters. Notably, increasing MitoPQ concentration to
0.1 μM disrupted [Ca2+]I homeostasis, causing the cells to become
unexcitable (Fig. 3). Overall, these findings demonstrate that ROS
produced within mitochondria alter [Ca2+]I homeostasis within the
cytosol and endoplasmic reticulum with different amounts of ROS
causing different effects.
Since oxidative stress associated with mitochondrial dysfunction is
known to decrease cell viability [46,47], we investigated whether Mi-
toPQ-induced oxidative stress could lead to cell death in NRVMs. The
loss of cell viability was measured as lactate dehydrogenase (LDH) re-
lease in NRVMs treated for 24 h with increasing doses of MitoPQ. Mi-
toPQ doses ≥0.5 μM significantly increased cell death (∼30%) which
could be abrogated by the addition of the free radical scavenger MPG
(Fig. 3F). Notably, 0.1 μM MitoPQ did not significantly alter cell via-
bility despite promoting ROS formation, mitochondrial dysfunction and
[Ca2+]I dyshomeostasis without mPTP opening. Therefore, we hy-
pothesized that the decreased cell viability at high concentrations of
MitoPQ was related to mPTP opening [48,49]. This was confirmed by
CsA treatment which prevented cell death induced by MitoPQ at doses
≥0.5 μM (Fig. 3G).
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2.4. Low levels of MitoPQ-induced ROS reduce cell death following anoxia/
reoxygenation
We demonstrated that low doses of MitoPQ (0.01 μM) elevated ROS
but did not alter mitochondrial function, [Ca2+]I homeostasis and cell
viability. Since an increase in mitochondrial ROS levels have been
proposed to be involved in IPC [5,50–52], we hypothesized that a
primary increase in non-toxic mitochondrial ROS levels by MitoPQ
might enhance tolerance to post-anoxic injury. To assess this, we
evaluated whether the low dose of MitoPQ could mimic the protection
elicited by IPC against anoxia/reoxygenation injury. Cells pre-treated
with 0.01 μM MitoPQ, with or without the antioxidant MPG, were ex-
posed to 12 h of anoxia followed by 1 h of reoxygenation. MitoPQ
treatment significantly decreased cell death both at the end of anoxia
and following reoxygenation. The cardioprotective effect of MitoPQ
was lost in cells treated with MPG (Fig. 4A). In addition, an identical
concentration of the MitoPQ control compound did not induce any
protection. Notably, the reliability of the protocol has been assessed by
the protective effect elicited by CsA in NRVMs exposed to anoxia/re-
oxygenation (Supplementary Fig. 2D). These data indicate that the in-
crease in cell viability was due to MitoPQ-induced ROS.
2.5. MitoPQ reduces infarct size in an in vivo model of ischaemia/
reperfusion injury
Finally, we utilised an in vivo surgical model of acute myocardial I/R
injury in the mouse to determine the effect of a primary increase of ROS
produced by MitoPQ upon infarct size. A bolus of MitoPQ was given by
i.v. injection 15min prior to the onset of cardiac ischaemia produced by
occlusion of the left anterior descending coronary artery. This was
followed by 2 h reperfusion. Elevating mitochondrial ROS by inter-
mediate doses of MitoPQ (i.e. 0.01–0.1 nmol) significantly reduced
infarct size compared to both DMSO-only control or MitoPQ control
compound (Fig. 4B-C-D). However, at both lower or higher doses of
MitoPQ no protection was observed, and a dose of 5 nmol MitoPQ was
fatal. This shows that low levels of mitochondrial ROS can be cardio-
protective during I/R injury in vivo, while higher levels of ROS cause
damage.
Considering the changes caused in cellular calcium dynamics ob-
served following treatment of NRVMs with MitoPQ, we evaluated its
effects on haemodynamics in vivo using dynamic measurements of left
ventricular pressure and volume. However no significant difference was
observed between animals injected with the most cardioprotective dose
of MitoPQ compared with hearts treated with vehicle only
(Supplementary Table 1).
3. Discussion
This study demonstrates that the primary formation of mitochon-
drial ROS exerts differential effects upon the heart during acute myo-
cardial I/R injury, with cardioprotection conferred by a narrow inter-
mediate dose range whilst no reduction in infarct size was observed at
either higher or lower doses. This primary increase in mitochondrial
ROS is also shown to have effects on mitochondrial function, [Ca2+]I
homeostasis and cell viability in a dose-dependent manner.
Until this point, studies assessing the effects of the alteration of
intracellular ROS levels have necessarily used crude approaches to
modulate ROS, which poorly mimic the (patho)physiological genera-
tion of ROS. For example, the application of exogenous hydrogen per-
oxide or exposure to a purine/xanthine oxygen radical generating
system both require the ROS to diffuse into the cell, rather than being
generated selectively within cell compartments such as the mitochon-
dria. These limitations have been addressed by using MitoPQ [31].
MitoPQ's mitochondrial accumulation allows it to be used at
Fig. 1. Effect of MitoPQ on ROS formation.Mitochondrial ROS formation monitored by: A)MTR in isolated NRVMs treated for 2 h with different concentrations of
MitoPQ or B) MitoPQ Control Compound, with or without 30min of pretreatment with 500 μM MPG. Scale Bar: 30 μm. C) Mitochondrial H2O2 formation measured
by MitoHyPer in isolated NRVMs treated for 2 h with different concentrations of MitoPQ, with or without 30min of pretreatment with 500 μM MPG. Scale Bar: 20 μm
D) Mitochondrial H2O2 formation measured by MitoHyPer in isolated NRVMs treated for 2 h with 0.5 μM MitoPQ or 0.5 μM MitoPQ Control Compound.
Approximately 70 cells were analysed per condition in each experiment and all the experiments were performed at least three times. Data are expressed as
mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 vs DMSO vehicle; #p < 0.05, ##p < 0.01, ###p < 0.001 vs MitoPQ.
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concentrations several hundred-fold lower than untargeted paraquat
and importantly this selective accumulation means that ROS are only
produced within mitochondria. The direct generation of superoxide
rather than downstream ROS also mirrors its production in (patho)
physiology as the proximal species [53]. This has been validated to
occur without detectable ROS production in the cytosol [54]. The dose-
dependent effect of MitoPQ on mitochondrial ROS production therefore
allows the generation of exogenous ROS in a highly specific manner.
Based on these features, MitoPQ represents a unique tool to investigate
and characterize the effects of a precise increase in mitochondrial ROS
formation on cell physiology, both in vitro and in vivo.
There is a growing body of evidence indicating that mitochondrial
ROS exert differential effects depending on their dose, which has been
called a “hormetic” dose-response curve [55]. In our experiments, high
levels of ROS induced by MitoPQ (i.e. 0.5–1 μM) lead to mitochondrial
dysfunction, mPTP opening and eventually cell death. Such detrimental
effects of ROS in I/R injury through the opening of the mPTP have been
well described [5]. Intermediate doses of ROS (i.e. 0.1 μM MitoPQ) did
not affect cell viability but did cause an alteration in the amplitude of
calcium transients and their response to caffeine. At low doses (i.e.
0.01 μM), ROS generation induced by MitoPQ slightly modulates
[Ca2+]I homeostasis without affecting either mitochondrial function or
cell viability. Importantly, isolated cardiomyocytes pre-treated with
low doses of MitoPQ and then exposed to anoxic injury displayed in-
creased cell viability. This in vitro result was paralleled by the reduction
of infarct size obtained in vivo in mice pre-treated with doses of MitoPQ
ranging from 0.01 nmol to 1 nmol per mouse. Therefore, mitochondrial-
derived ROS elicit a wide range of responses which are dependent on
their dose, ranging from the disruption of ΔΨm and mPTP opening at
high doses of MitoPQ to the reduction of cell death and infarct size at
low doses of MitoPQ in a preconditioning-like manner. The absence of
protective effects observed with both low and high doses of MitoPQ in
vivo (i.e. 0.001–1 nmol) highlights the hormetic effect elicited by in-
termediate levels of ROS. Moreover, higher doses of MitoPQ (i.e. 2.5 –
10 nmol) displayed to be lethal in vivo. The concept of hormesis helps to
rationalize the paradoxical effect of both injury and protection elicited
by ROS described in literature, as well as the failure of clinical trials
using general administration of antioxidants.
The data presented also show that a number of ROS-related events
spread from mitochondria to the cytosolic compartment. As the source
of ROS generation in our experiments is within mitochondria, we pro-
vide the first direct evidence that a primary increase in mitochondrial
ROS formation can induce cardioprotection both in vitro and in vivo via
changes in mitochondrial and cellular function. The known interplay
between ROS and [Ca2+]I homeostasis is of central relevance to the
cardiomyocyte and has specifically been implicated in several disease
states [56], but it has been difficult to determine the primacy of one
factor upon the other. Taken together, our findings show that a primary
increase in mitochondrial ROS can impact on the cytosol, altering
[Ca2+]I homeostasis and thereby whole cell function.
It is worth noting that while we have determined the doses of
MitoPQ associated with the various effects in mitochondria and in in-
tact cells, the actual concentrations of ROS required for cardiomyocytes
injury and protection remain to be established due to the technically
Fig. 2. Effects of MitoPQ on mitochondrial membrane potential and mPTP opening. A) Mitochondrial membrane potential (ΔΨm) monitored by TMRM
fluorescence in isolated NRVMs following incubation for 2 h with MitoPQ at different concentrations a: 4 μM oligomycin, b: 4 μM FCCP. B) mPTP opening monitored
by decrease of calcein fluorescence in isolated NRVMs pretreated for 30min with or without 1 μM CsA or 500 μM MPG. a: treatment with DMSO as control or 0.5 μM
MitoPQ; b: 5 μM Calcimycin. Data were quantified 12 min after treatment with MitoPQ/DMSO. Approximately 30 cells were analysed per condition in each
experiment and all the experiments were performed at least three times. Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 vs DMSO
vehicle; #p < 0.05, ##p < 0.01, ###p < 0.001 vs MitoPQ.
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challenging nature of their measurement, especially in vivo [57].
Moreover, since we have utilised healthy young male animals for our in
vivo model it remains to be seen how comorbidities such as obesity,
diabetes, aging and sex modulate the response to a given quantity of
mitochondrial ROS, since for example the protective efficacy of IPC is
lost in aged or diabetic hearts [51].
In conclusion, we have demonstrated that a primary increase in
mitochondrial ROS exerts effects on both mitochondrial and cell func-
tion, which presents mitochondrial ROS as a cause rather than con-
sequence of the functional change in cardiac (patho)physiology.
Fig. 3. Effects of MitoPQ on cytosolic [Ca2+] homeostasis and cell viability. A-E) cytosolic [Ca2+] homeostasis monitored by Fluo-4 AM in isolated NRVMs
treated for 2 h with different concentrations of MitoPQ. A) Comparison between cytosolic Ca2+ oscillatory patterns. a: 10mM caffeine. B) Peak amplitude average; C)
Area Under Curve (AUC) average; D) Peaks Frequency average; E) Average caffeine Peak amplitude. F-G) Cell death monitored by LDH released from isolated NRVMs
treated for 24 h with different concentrations of MitoPQ and pretreated with or without F) 500 μM MPG or G) 1 μM CsA. A-E: Approximately 30 cells were analysed
per condition in each experiment and all the experiments were performed at least three times. Data are expressed as mean ± SEM. F-G: Approximately 4 wells (cell
density: 1.5× 105 cells/well in 24 wells plates) were analysed per condition in each experiment and all the experiments were performed at least three times. Data are
expressed as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 vs DMSO vehicle; #p < 0.05, ##p < 0.01, ###p < 0.001 vs MitoPQ.
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Notably, the generation of exogenous ROS by MitoPQ within mi-
tochondria is found to exert differential effects, with a hormetic dose
response curve in which protection is observed only at an intermediate




Neonatal rat ventricular myocytes (NRVMs) were isolated from 1 to
3 day old Wistar rats as described previously [58]. Briefly, hearts were
excised, cut into smaller pieces and left overnight at 4 °C for digestion
by 2.5% trypsin 10× (Thermo Fisher Scientific) in HBSS (Sigma). The
next day, tissues were incubated with 0.75mg/ml collagenase type II
(Thermo Fisher Scientific) in HBSS for 10min (at 2min intervals) at
37 °C and cells dissociated by pipetting. Following centrifugation at
300g for 7min, cells were resuspended in MEM (Invitrogen) and pre-
plated for 2 h to let cardiac fibroblasts attach to the plastic surface.
Plates and coverslips were coated with a solution of 0.1% porcine ge-
latin (Sigma) and incubated at 37 °C for 1 h. The non-adherent myo-
cytes were plated in gelatin coated plates at variable density (at least
1× 105 cells/ml) in MEM supplemented with 10% FBS (Thermo Fisher
Scientific), 1% penicillin/streptomycin (Thermo Fisher Scientific), 1%
non-essential amino acids (Thermo Fisher Scientific), 1 mM 5-Bromo-2-
Deoxyuridine (Sigma). Cells were maintained at 37 °C in presence of 5%
CO2. The medium was changed to MEM supplemented with 1% FBS, 1%
penicillin/streptomycin and 1% non-essential amino acids after 24 h of
plating.
To evoke a primary increase in mitochondrial ROS, NRVMs were
treated in culture medium with different concentrations of MitoPQ
[31], from 0.01 to 1 μM for 2 h, unless specified in results. A MitoPQ
control compound was also used that has a very similar structure to
MitoPQ and similar levels of uptake into mitochondria, but which
cannot generate ROS by redox cycling. MitoPQ redox cycles because it
can receive an electron from the FMNH2 of complex I reducing the
viologen dication to a radical cation, which then reduces oxygen to
superoxide to regenerate MitoPQ (Supplemental Fig. 1). MitoPQ control
employs the twisted viologen unit described by Ref. [59], in which two
extra methyl groups disfavour the coplanarity of the two pyridine units
required to stabilize a radical cation. We have previously reported its
use [60], but here give full details of its synthesis in two steps by double
alkylation of 3’-dimethyl-4,4’-dipyridyl, prepared by the procedure of
(Rebek et al., 1985) (Supplementary Fig. 3). To scavenge ROS, cells
were pre-treated with 500 μM MPG (Sigma) [61] for 30min. To prevent
mPTP opening, cells were pre-treated with 1 μM CsA (Sigma) [62] for
30min.
Fig. 4. Effects of MitoPQ on cardiomyocytes viability both in vitro and in vivo. A) Cell death measured by LDH release from isolated NRVMs treated for 2 h with
0.01 μM MitoPQ or 0.01 μM MitoPQ control compound, with or without 500 μM MPG. *p < 0.05 vs DMSO Anoxia, ###p < 0.001 vs DMSO Reoxygenation,
§§p < 0.01 vs MitoPQ. B) Representative infarct slices from hearts treated with vehicle, MitoPQ control compound 0.01 nmol MitoPQ. C) Infarct size in hearts of
mice exposed to acute myocardial I/R, in presence or absence of 0.01 nmol MitoPQ control compound or the indicated dose of MitoPQ. *p < 0.05 vs DMSO. D) Risk
zone in heart of mice exposed to acute myocardial I/R, in presence or absence of 0.01 nM MitoPQ control compound or the indicated dose of MitoPQ. A: at least 4
wells (cell density: 1.5× 105 cells/well in 24 wells plates) were analysed per condition in each experiment and all the experiments were performed at least three
times. Data are expressed as mean ± SEM. B-D: n= 6-8. Data are expressed as mean ± SEM. #p < 0.05. Overall Anova p=0.0053.
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4.1.2. Transfection
NRVMs were plated on six-well plates at a density of 3× 105 cells/
well and transfected with Lipofectamine 3000 reagent (Sigma). For
each transfection, 2.5 μg of MitoHyPer (Evrogen) was diluted in 125 μl
of Opti-MEM medium (Thermo Fisher Scientific) in presence of 5 μl of
P3000™ reagent (Life Technologies) and later combined with 4 μl of
Lipofectamine™ 3000 (Life Technologies). The DNA-lipid complexes
were added to the cells and incubated overnight. The day after, cells
were rinsed with PBS and new MEM was added. Transfected cells were
used for experiments after 48 h.
4.1.3. Imaging
Experiments using NRVMs were carried out in HBSS at pH 7.4
(adjusted with NaOH) and at 37 °C.
Images were acquired using an inverted fluorescence microscope
(Leica DMI6000B equipped with DFC365FX camera) with PL APO
40×/1.25 oil objective. Fluorescence intensity was quantified using the
Fiji distribution of the Java-based image processing program ImageJ
[63], and background signal was subtracted from all analysed regions
of interest. For Ca2+ imaging, traces were analysed using the “Peak
Analyzer” tool of Origin Pro 9.1.
To monitor mitochondrial ROS formation, cells were incubated with
25 nM MitoTracker Red CM-H2XRos (MTR, Thermo Fisher Scientific)
for 30min at 37 °C in a humidified incubator. Since the accumulation of
MTR in NRVMs can vary from different preparation, data were nor-
malized to DMSO control.
To monitor mitochondrial membrane potential (ΔΨm), cells were
incubated with 25 nM tetramethylrhodamine (TMRM, Thermo Fisher
Scientific) in presence of 1.6 μM cyclosporin H (CsH) for 30min at 37 °C
in a humidified incubator. TMRM fluorescence intensity was monitored
following addition of 4 μM oligomycin (Sigma) and images were ac-
quired before and after the addition of 4 μM carbonyl cyanide-p-tri-
fluoromethoxyphenylhydrazone (FCCP, Sigma) [58]. In order to have a
reliable value of TMRM, fluorescence values were expressed as ΔF (F0/
FFCCP) and results were normalized to DMSO control basal value.
To monitor mPTP opening, cells were incubated with 1 μM calcein
acetoxymethyl (AM) ester (Thermo Fisher Scientific) in presence of
1mM Cobalt Chloride (CoCl2) for 15min at 37 °C in a humidified in-
cubator as previously described [42]. To evaluate the extent of pore
opening, data were normalized to the basal value.
To monitor [Ca2+]I homeostasis, cells were incubated with 5 μM
Fluo-4 AM ester (Thermo Fisher Scientific), 0.01% w/v pluronic F-127
(Sigma) and 250 μM sulfinpyrazone (Sigma), for 20min at 37 °C in
MEM followed by 20min of de-esterification. Since the accumulation of
Fluo-4 in NRVMs can vary from different preparation, data were nor-
malized to DMSO control.
4.1.4. Assessment of cell death
For normoxic experiments, NRVMs were seeded in 24w plates at
density of 105 cells/well and cultured in MEM supplemented with 1%
FBS, 1% penicillin/streptomycin and 1% non-essential amino acids.
Cells were incubated with different concentrations of MitoPQ with or
without MPG or CsA for 24 h at 37 °C in a humidified incubator.
For anoxia/reperfusion experiments, NRVMs were seeded in 24w
plates at density of 105 cells/well and incubated in 118mM NaCl, 5 mM
KCl, 1.2mM KH2PO4, 1.2mM MgSO4, 2mM CaCl2, 25mM MOPS at pH
6.4 during anoxia or pH 7.4 during reoxygenation [64]. Anoxia was
induced adding 10mM 2-deoxy-D-glucose (2-DG) and incubating in a
BD GasPak™ EZ Anaerobe Gas-generating Pouch System with an in-
dicator (BD Biosciences) at 37 °C for 12 h [65]. To induce reoxygena-
tion, plates were removed from the GasPak™ pouch, 2-DG was replaced
with 10mM D-glucose, the pH was restored at 7.4. The plates were then
incubated for 1 h in a humidified incubator at 37 °C.
The release of LDH from NRVMs was measured to evaluate cell
death occurring in normoxia, anoxia and reoxygenation as described
before [62,66]. Supernatant aliquots were collected after 24 h of
normoxia, 12 h of anoxia and 1 h of reoxygenation. At the end of every
experiment, intact cells were lysed by incubating with 1% Triton X-100
(Sigma) for 30min and supernatants were collected to evaluate the
total amount of LDH. LDH enzymatic activity was measured spectro-
photometrically by the absorbance of nicotinamide adenine dinucleo-
tide (Roche) at 340 nm, indicative of the reduction of pyruvate to lac-
tate.
4.2. Experimental animals
Male C57BL/6 J mice aged 8–10 weeks (22–32 g) were obtained from
Charles River, UK. They were housed under standard laboratory condi-
tions, with food and water available ad libitum. All procedures were carried
out in accordance with the UK Home Office Guide on the Operation of
Animal (Scientific Procedures) Act 1986 and University of Cambridge
Animal Welfare Policy under project licenses 70/8238 and 70/7963.
4.3. Open-chest mouse model of acute myocardial I/R injury
An open chest model of acute myocardial ischaemia/reperfusion
injury was used as described elsewhere [67]. Mice were anesthetized
with sodium pentobarbital (70mg/kg intraperitoneal), with depth of
anaesthesia monitored via the pedal reflex and additional anaesthesia
administered as required. Following left side lateral thoracotomy, the
left anterior descending coronary artery was occluded for 30min fol-
lowed by 2 h of reperfusion. Compounds were administered 15min
prior to the start of ischaemia by an intravenous bolus injection in the
lateral tail vein.
At the end of the protocol, the area at risk was delineated by ret-
rograde injection of 10mg/ml Evans Blue after re-occlusion of the left
anterior descending coronary artery. Heart sections were incubated for
25min at 37 °C in 1% triphenyltetrazolium chloride (Sigma, UK) before
fixing for 24 h in 10% formalin. Planimetry was performed in a blinded
fashion using ImageJ [68]. Hearts in which the area at risk was outside
of the range 30%–60% of total area were excluded from any further
analysis.
4.4. Pressure-volume analysis of cardiac function
Anaesthesia was induced with 3% isoflurane in O2 in a plexiglass
chamber. Mice were transferred to a heated surgical platform, and
sufficient isoflurane administered to maintain anaesthesia as assessed
by the pedal reflex. Body temperature was maintained at 37 °C using a
rectal thermometer and temperature controller (TCAT-2LV, Physitemp,
USA). The left ventricle was catheterized via the right carotid artery
with a 1.2 French tetrapolar catheter (Transonic Scisense Inc, Canada)
as described elsewhere [69]. In brief, a small midline incision was made
in the neck in order to expose the carotid artery and isolate it from the
vagus nerve. A 4-0 silk suture was tied tightly around the distal end of
the artery, and two more sutures were placed loosely at the proximal
end. Using a vascular clamp (0.4–1mm) to minimise blood loss, a small
incision was made in the carotid artery with microscissors and the ca-
theter inserted and secured using the additional sutures. The catheter
was the inserted along the carotid until it was located centrally within
the left ventricle, as indicated by the phase signal and by the shape of
the resultant pressure-magnitude loops. At least 15min were allowed
for the haemodynamics to stabilize. A 100 μL bolus containing either
0.1 nmol MitoPQ or vehicle only was then injected via the lateral tail
vein. Data were recorded at 1000 Hz using the ADV500 PV system
(Transonic Scisense Inc, Canada) and a multi-channel acquisition
system (Powerlab, ADInstruments, UK) and were analysed in LabChart
(ADInstruments, UK). Volumes were calculated on dynamic basis using
Wei's equation [70]. Three short sections of loops (within one breathing
cycle) were examined at both baseline conditions and> 5min fol-
lowing injection. Upon completion of the protocol all animals were
killed via cervical dislocation.
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4.5. Chemical synthesis
MitoPQ was synthesized from iododecyl-TPP salt 1, which was
prepared as described previously [31] (Supplementary Fig. 3). This was
reacted with an excess of 3,3'-dimethyl-4,4’-dipyridyl 2, prepared by
the procedure of (Rebek et al. [71]), to minimise dialkylation. The
monoalkylated product 3 was isolated in excellent yield and was then
methylated to give complete conversion to MitoPQ control. Original




(10-Iododec-1-yl)triphenylphosphonium iodide 1 (107mg,
0.163mmol, 1.0 eq.) was added to a solution of 3,3’-Dimethyl-4,4’-di-
pyridyl 2 (120mg, 0.65mmol, 4.0 eq) in MeCN (2ml) and the resulting
solution was heated to 60 °C overnight under an atmosphere of argon.
The solution was cooled to RT and concentrated under vacuum. Column
chromatography eluting with CH2Cl2-MeOH (100:0 to 85:15) then gave
the pyridinium salt 3 as an off-white solid (116mg, 85%). νmax (ATR):
2926 (CH), 2854 (CH), 1635 (Ar), 1437 (CH) cm−1. δH (400MHz,
CDCl3): 9.98 (1H, s, H-1), 9.71 (1H, d, J=6.3 Hz, H-2), 8.62 (1H, s, H-
4), 8.58 (1H, d, J=5.0 Hz, H-5), 7.86–7.68 (16H, m, PPh3 + H-3),
7.06 (1H, d, J=4.9 Hz, H-6), 4.97 (2H, t, J=7.8 Hz, NCH2), 3.61–3.51
(2H, m, PCH2), 2.37 (3H, s, CH3), 2.32–2.16 (2H, m, NCH2CH2), 2.10
(3H, s, CH3), 1.70–1.60 (8H, m, 4×CH2), 1.59–1.50 (2H, m, CH2),
1.49–1.25 (4H, m, 2×CH2). δC (101MHz, CDCl3): 154.85 (C), 151.42
(CH), 147.46 (CH), 145.16 (CH), 142.50 (CH), 137.03 (C), 134.94 (d,
J=3.0 Hz, CH), 133.25 (d, J=10.0 Hz, CH), 130.32 (d, J=12.6 Hz,
CH), 129.32 (C), 127.45 (CH), 121.39 (CH), 117.60 (d, J=86.0 Hz, C),
60.75 (CH2), 31.17 (CH2), 29.81 (d, J=15.8 Hz, CH2), 28.26 (CH2),
28.17 (CH2), 27.99 (CH2), 27.96 (CH2), 25.41 (CH2), 22.70 (d,
J=50.4 Hz, CH2), 22.11 (d, J=4.4 Hz, CH2), 16.81 (CH3), 16.48
(CH3). δP (162MHz: CDCl3): 23.94 (s). m/z (ESI): Found: 293.1734.
C40H47N2P requires (M2+), 293.1733.
4.5.2. 1,3,3’-trimethyl-1’-(10‴-triphenylphosphoniodec-1‴-yl)-4,4’-
bipyridinium (MitoPQ control) triiodide
Iodomethane (19 μl, 0.29mmol, 5.0 eq.) was added to a solution of
pyridine 3 (49mg, 0.058mmol, 1.0 eq) in MeCN (1ml) and the re-
sulting solution was heated to 40 °C overnight under an atmosphere of
argon. The solution was cooled to RT and concentrated under vacuum
to give the MitoPQ triiodide as an off-white solid (57mg, 100%). νmax
(ATR): 3016 (CH), 2926 (CH), 2854 (CH), 1635 (Ar), 1437 (CH) cm−1.
δH (400MHz, d3-MeCN): 9.14 (1H, s, H-1), 8.94 (1H, s, H-4), 8.91 (1H,
d, J=6.3 Hz, H-2), 8.77 (1H, d, J= 6.3 Hz, H-5), 7.99–7.86 (5H, m, H-
3, H-6 + 3 × ArH), 7.81–7.71 (12H, m, 12 × ArH), 4.67 (2H, t,
J=7.6 Hz, NCH2), 4.42 (3H, s, NCH3), 3.35–3.23 (2H, m, PCH2), 2.30
(3H, s, CH3), 2.29 (3H, s, CH3), 2.07 (2H, q, J=7.3 Hz, NCH2CH2),
1.70–1.60 (2H, m, PCH2CH2), 1.58–1.49 (2H, m, CH2), 1.47–1.25 (10H,
m, 5×CH2). δC (101MHz, d3-MeCN): 152.15 (C), 147.69 (CH), 146.81
(CH), 143.92 (CH), 143.12 (CH), 138.41 (C), 137.98 (C), 135.86 (d,
J=3.0 Hz, CH), 134.55 (d, J=10.0 Hz, CH), 130.07 (d, J=12.5 Hz,
CH), 128.04 (CH), 127.81 (CH), 119.31 (d, J=86.2 Hz, C), 62.20
(CH2), 49.19 (CH3), 31.74 (CH2), 30.76 (d, J=16.2 Hz, CH2), 29.55
(CH2), 29.48 (CH2), 29.30 (CH2), 29.04 (CH2), 26.35 (CH2), 22.81 (d,
J=4.4 Hz, CH2), 22.61 (d, J=50.7 Hz, CH2), 17.54 (CH3), 17.41
(CH3). δP (162MHz: d3-MeCN): 23.84 (s). m/z (ESI): Found: 200.4568.
C41H50N2P requires (M3+), 200.4565.
4.6. Data analysis
All values are expressed as mean ± S.E.M. Every set of data has 3
biological replicates (i.e. 3 different cardiac preparations) and every
biological replicate has at least 3 technical replicates (i.e. 3 different
samples of the same preparation). The propagation of error analysis was
performed to take into account the uncertainty that is present in the
experimental measurements due to measurement limitations (i.e. dif-
ferent accumulation of the sensor in NRVMs derived from different
preparations). Comparison between groups was performed by one-way
ANOVA, followed by post hoc testing (i.e. Tukey's range test, Dunnett's
test) adjusted for multiple comparisons where data were normally
distributed. Data that did not follow the normal distribution were sta-
tistically analysed by Kolgomorov-Smirnov's test. Comparison between
two groups was performed using a two-tailed Student's t-test, with
correction for multiple testing by the Bonferroni method where ap-
propriate. A value of p < 0.05 was considered significant.
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mPTP Mitochondrial permeability transition pore
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